Want to join the conversation?
$PFE's revenue from Innovative Products for 4Q15 rose by 15% from last year with Global Innovative Pharmaceuticals (GIP) revenue rising 10% operationally due to the strong operational performance of Eliquis globally. Established Products revenue fell 2% while Global Established Pharmaceutical (GEP) revenue rose 5% operationally.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.